Compare 8x8 Inc (EGHT) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs Incyte Corporation — how do they compare? 8x8 Inc trades at $2.11 (market cap $311.98M), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 73.2× 8x8 Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, 8x8 Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 8x8 Inc for 16 Days and Incyte Corporation for 33 Days on average.
| EGHT | INCY | |
|---|---|---|
Market Cap | $311.98M | $22.85B |
Volume | 1,639,086 | 1,927,029 |
Sector | Technology | Health |
52-Week High | $2.76 | $129.93 |
52-Week Low | $1.59 | $83.80 |
Typical Hold Time | 16 Days | 33 Days |
Enterprise Value | $578.90M | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.13, down 0.47% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth with $715M in 2025 and positive earnings beats in recent quarters, though profitability remains challenged with a net loss of $27M. Recent news highlights cost-saving customer implementations and AI platform growth, while analyst consensus is mixed with a $19.77 price target representing significant upside potential.
EGHT presents a high-risk, high-reward opportunity with substantial analyst upside but faces execution risks amid competitive pressures. The stock's current valuation at 72x P/E reflects growth expectations, but investors must weigh the company's debt load and margin challenges against its strategic positioning in cloud communications and AI innovation.
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
